Efficacy and Tolerability of Intravenous V/s Oral Iron for IDA in IBD Patients: A Systematic Review and Meta-Analysis
1 Department of Internal Medicine, GMERS Medical College and Hospital, Vadodara, India.
2 Department of Medicine, Faculty of Medicine, Al- Azhar University, Asyut, Egypt.
3 Department of Medicine, Faculty of Health Sciences, University of Nairobi, Nairobi, Kenya.
4 Department of Emergency, Obafemi Awolowo University Teaching Hospitals Complex, Ileife, Nigeria.
Review Article
World Journal of Advanced Research and Reviews, 2023, 18(03), 1439–1447
Article DOI: 10.30574/wjarr.2023.18.3.1246
Publication history:
Received on 16 May 2023; revised on 25 June 2023; accepted on 28 June 2023
Abstract:
Background and Aims: Anemia is the most common extraintestinal complication of inflammatory bowel diseases (IBD). Iron deficiency anemia (IDA) can be treated with oral or intravenous (IV) iron supplementation. The aim of this study is to compare the efficacy and tolerability of oral and IV iron supplementation for treating anemia in adult IBD patients.
Methods: A systematic review and meta-analysis of randomized controlled trials were conducted. Databases including PubMed, Web of Science, Scopus, and Cochrane Central Register of Controlled Trials were searched until December 2022. Trials that included individuals with IBD and compared IV to oral iron for treating IDA were eligible. Two reviewers independently extracted data, and another two reviewers independently graded each trial's risk of bias. The fixed-effect model was used to obtain pooled odds ratio (OR) estimates and their 95% confidence intervals (CI).
Results: Five trials, including 910 IBD patients, were eligible for analysis. The meta-analysis showed that IV iron was more effective than oral iron for raising hemoglobin levels to 2.0 g/dL (OR: 1.44, 95% CI: 1.09 - 1.91, P = 0.01). The IV iron groups had decreased rates of treatment withdrawal prompted by adverse side effects or intolerance (OR: 0.26, 95% CI: 0.13 - 0.51, P < 0.0001). There was no evidence of heterogeneity across all studies.
Conclusion: IV iron appears to be more efficient and well-tolerated than oral iron for treating anemia associated with IBD. The findings suggest that IV iron may be a preferred treatment option for IBD patients with IDA.
Keywords:
Crohn`s disease; Ulcerative colitis; Iron supplementation; Iron deficiency
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0